Screener
Altimmune ALT G&A
G&A at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Altimmune’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326190-26-000040
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Revenues | — | $5 |
| Operating expenses: | ||
| Research and development | 16,192 | 15,827 |
| General and administrative | 8,052 | 5,993 |
| Total operating expenses | 24,244 | 21,820 |
| Loss from operations | (24,244) | (21,815) |
| Other income (expense): | ||
| Interest expense | (1,068) | (1) |
Item 1. Financial Statements
FAQ
- What is Altimmune's G&A?
- Altimmune (ALT) reported G&A of $8.05M in Q1 2026.
- How has Altimmune's G&A changed year-over-year?
- Altimmune's G&A increased by 34.4% year-over-year, from $5.99M to $8.05M.
- What is the long-term trend for Altimmune's G&A?
- Over 4 years (2021 to 2025), Altimmune's G&A has grown at a 16.2% compound annual growth rate (CAGR), from $15.41M to $28.1M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Altimmune's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude